10 drugmakers with highest direct-to-consumer ad spending in 2016

The pharmaceutical industry spent 9 percent more on direct-to-consumer ads in 2016 than in the year prior, with total spending reaching $5.6 billion, according to a Medical Marketing & Media report.

For the report, researchers analyzed Nielsen data on television, magazine, radio, newspaper, business-to-business, outdoor and cinema media spend. The analysis did not include digital spend.

Here are the 10 drugmakers that spent the most on direct-to-consumer ads in 2016, according to the report.

1. Pfizer — $1.19 billion

2. Bristol-Myers Squibb — $458 million

3. AbbVie — $433 million

4. Eli Lilly — $414 million

5. Allergan — $352 million

6. Johnson & Johnson — $291 million

7. Merck — $285 million

8. Novartis — $254 million

9. AstraZeneca — $225 million

10. Novo Nordisk — $206 million

More articles on supply chain:

4 reasons supply chain managers could one day become CEOs
Can employers lower drug spending by limiting PBM involvement in health plans? 4 thoughts
5 trends shaping today's supply chain industry

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Webinars

Featured Whitepapers